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Limb-girdle muscular dystrophy type 2H (LGMD2H) is a mild autosomal recessive myopathy that was first described
in the Manitoba Hutterite population. Previous studies in our laboratory mapped the causative gene for this disease
to a 6.5-Mb region in chromosomal region 9q31-33, flanked byD9S302 andD9S1850.We have now used additional
families and a panel of 26 microsatellite markers to construct haplotypes. Twelve recombination events that reduced
the size of the candidate region to 560 kb were identified or inferred. This region is flanked by D9S1126 and
D9S737 and contains at least four genes. Exons of these genes were sequenced in one affected individual, and four
sequence variations were identified. The families included in our study and 100 control individuals were tested for
these variations. On the basis of our results, the mutation in the tripartite-motif–containing gene (TRIM32) that
replaces aspartate with asparagine at position 487 appears to be the causative mutation of LGMD2H. All affected
individuals were found to be homozygous for D487N, and this mutation was not found in any of the controls.
This mutation occurs in an NHL (named after the proteins NCL1, HT2A, and LIN-41) domain at a position that
is highly conserved. NHL domains are known to be involved in protein-protein interactions. Although the function
of TRIM32 is unknown, current knowledge of the domain structure of this protein suggests that it may be an E3-
ubiquitin ligase. If proven, this represents a new pathogenic mechanism leading to muscular dystrophy.
Introduction
The limb-girdle muscular dystrophies (LGMDs) are a
heterogeneous group of primary myopathies with
both autosomal dominant and autosomal recessive
modes of inheritance (Bushby 1999a; Kaplan 2001).
Recessively inherited forms LGMD2A–LGMD2I map
to nine loci. The two most common types are
LGMD2A and LGMD2B, which are caused by mu-
tations in the genes encoding calpain 3 and dysferlin,
respectively. LGMD2C–LGMD2F are caused by mu-
tations in members of the sarcoglycan complex, and
LGMD2G is caused by mutations in the gene for the
sarcomeric protein telethonin. The genes responsi-
ble for LGMD2H and LGMD2I have not yet been
identified.
LGMD2H (MIM 254110) is a mild form of autosomal
recessive muscular dystrophy, with a variable clinical pre-
sentation (Shokeir and Kobrinsky 1976; Weiler et al.
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1997; Bushby 1999b). Onset is usually within the 2d or
3d decade of life, and progression is slow. Most patients
have remained ambulatory into the 6th decade of life.
There is no evidence of cardiac or facial involvement. To
date, this disease has been described only in the Hutterite
population of North America (Shokeir and Kobrinsky
1976; Shokeir and Rozdilsky 1985; Weiler et al. 1997).
Our group recently mapped the locus for LGMD2H
to an interval, flanked by D9S302 and D9S1850, in
chromosomal region 9q31-33 (Weiler et al. 1998),
which is now estimated to be 6.5 Mb (University of
California–Santa Cruz [UCSC] Human Genome Project
Working Draft). Herein, we describe the fine mapping
and characterization of the LGMD2H candidate region.
This was achieved by haplotype analysis and compar-
ison of sequences from an affected individual and se-
quences generated by either the Human Genome Project
(Lander et al. 2001) or Celera Genomics (Celera Publi-
cation Site; Venter et al. 2001). We sequenced genes in
the candidate region for pathogenic mutations and iden-
tified TRIM32 as the most likely gene for LGMD2H.
TRIM32 is a member of the tripartite-motif (TRIM) fam-
ily of proteins described elsewhere (Reymond et al. 2001).
Current views of the domains that are characteristic of
this protein family suggest that TRIM32 may be involved
in the ubiquitin (Ub)–proteasome pathway (Joazeiro and
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Weissman 2000). This pathway has not previously been
implicated in muscular dystrophy and therefore repre-
sents a novel pathogenic mechanism.
Subjects and Methods
Subjects
We studied 35 clinically affected Hutterite patients
and members of their immediate families. Signed in-
formed consent was obtained from each individual, and
the study was approved by the University of Manitoba
research-ethics board. Genotypes were obtained for
117 individuals, who constitute six interrelated families
(two to four generations) with 2–12 family members
affected with LGMD2H. Samples of DNA from 100
individuals not known to have LGMD or to be related
to the Hutterites were used as controls; no demographic
or ethnic information for these individuals was avail-
able to us. Eight Centre d’E´tude du Polymorphisme
Humain (CEPH) families with recombinations in chro-
mosomal region 9q3 (S. Povey, personal communica-
tion) were used to help define marker order; CEPH
individuals 1331-01, 1331-02, 1347-01, and 1347-02
were used to determine the size of microsatellite alleles
(Fondation Jean Dausset–CEPH).
DNA Analysis
Genotypes were obtained as described elsewhere
(Weiler et al. 1998). Haplotypes were constructed man-
ually, by minimizing the number of recombinants and
assuming no mutation of marker alleles. The candidate
region was defined on the basis of observed or inferred
ancestral recombination events.
Oligonucleotide primers (see table S1, available online
only) were designed to amplify exons of the candidate
genes from genomic DNA, for single-stranded confor-
mational analysis (SSCA) and/or sequencing. For most
exons of 1350 bp, overlapping primers were designed.
SSCA was performed on PCR products from three in-
dividuals: one patient and two siblings (one of whom
has one disease-associated chromosome and the other
of whom has no disease-associated chromosomes). The
analysis was performed under three conditions: (a) 6%
acrylamide (19:1) with 10% glycerol at 20C, with 8
mA, for 20 h; (b) 6% acrylamide (19:1) with 20% glyc-
erol at 4C, with 10 W, for 20 h; and (c) MDE gel per
manufacturer’s instructions (FMC BioProducts). PCR
products to be sequenced were separated by electropho-
resis in 1% agarose gels. DNA fragments were purified
from gel slices by GenElute (Sigma-Aldrich). The frag-
ments were then sequenced, with the same primers used
to generate the PCR products, on an ABI 377 DNA
sequencer (Applied Biosystems) at the Centre for Applied
Genomics, the Hospital for Sick Children, Toronto. Pu-
tative mutations were identified by comparing the se-
quence obtained from the patient and the published se-
quences (GenBank; Celera Publication Site). DNA from
an unaffected sibling was then sequenced to confirm the
existence of two different alleles.
PCR assays based on either length variation or re-
striction-enzyme digestion were developed to screen the
variations that were identified by DNA sequencing. The
six Hutterite families included in this study and 100
control individuals were tested for the presence of each
variation. All fragments were subjected to electropho-
resis in an 8% acrylamide gel and were visualized by
ethidium bromide staining unless otherwise specified.
We named the mutations according to the recommen-
dations of the Nomenclature Working Group (Anton-
arakis and Nomenclature Working Group 1998). The
four variations were studied as follows (for description
of each sequence variation, see table 1):
V1. Genomic DNA was amplified using primers
PAPPA_ex.3F (5′-GCTCTAAATTATTTGGAGAGG-3′)
and PAPPA_ex.3R (5′-GCACTAAGTGTATTACTG-
TCC-3′). The 11-bp deletion was readily visible as a
shift in fragment size (from 291 to 280 bp) in 12%
polyacrylamide gels.
V2. Genomic DNA was amplified using primers
designed with a mismatch (denoted by a lowercase let-
ter), P14_BsmAIF (5′-GCTGGCTGTGGAGAATGCgT-
3′) and P14_BsmAIR (5′-AGCACCTGCACATACCT-
GtC-3′). P14_BsmAIR creates a BsmAI restriction site
in all fragments, whereas P14_BsmAIF creates a BsmAI
site only in the V2(Ser) allele. Restriction-enzyme di-
gestion of the V2(Ser) allele by BsmAI yields three frag-
ments (94, 24, and 27 bp), whereas the V2(Tyr) allele
has two fragments (118 and 27 bp).
V3. Genomic DNA was amplified using primers
PAPPA_ex.18F (5′-CTCTCTTGGTCCTAACTCTG-3′)
and PAPPA_ex.18R (5′-GAATTGCCCCTCCTACTGC-
3′). Restriction-enzyme digestion of the V3(C) allele
yields two fragments (162 and 63 bp), whereas the V3(T)
allele migrates as a single fragment (225 bp).
V4. Genomic DNA was amplified using primers
HT2A_ex.2(5)F (5′-GGTGTGACTGACAGCTATG-3′)
and H2_HpyR (5′-AGCTTTCCACCTTCCACgT-3′).
H2_HpyR was designed with a mismatch (denoted by a
lowercase letter) that creates an Hpy99I restriction site
only in the V4(Asp) allele. Digestion of the V4(Asp) allele
yields two fragments (136 and 16 bp), whereas the
V4(Asn) allele migrates as a single fragment (152 bp).
Expression Analysis
A 12-tissue northern blot obtained from Origene
Technologies was used to determine the normal distri-
bution of the TRIM32 transcript. A TRIM32 probe was
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Table 1
Four Sequence Variations Found in Exons within the LGMD2H Candidate Region
MUTATION GENE (LOCATION) SEQUENCE VARIATION(S)a VARIATION TYPE(S)
CONTROL INDIVIDUALS
Genotypeb No.
V1 PAPPA (intron 2) c.(1479-59)–(1479-49)del Deletion / 27
/ 50
/ 23
V2 PAPPA (exon 14) c.3671CrA, p.S1224Y Transversion, missense mutation Ser/Ser 8
Ser/Tyr 33
Tyr/Tyr 59
V3 PAPPA (exon 18) c.4374CrT, p.C1458C Transition, silent mutation C/C 96
C/T 4
T/T 0
V4 TRIM32 (exon 2) c.1459GrA, p.D487N Transition, missense mutation Asp/Asp 100
Asp/Asn 0
Asn/Asn 0
a Numbering of nucleotides and amino acids is based on GenBank (accession number NM_002581.1 for PAPPA and accession number
NM_012210.2 for TRIM32); the A of the initiator Met codon is considered to be nucleotide 1.
b For V1, the presence or deletion of 11 bp is denoted by  or , respectively; for V2 and V4, alleles are denoted by amino acid codes;
and, for V3, alleles are denoted by nucleotides.
prepared by amplifying a 733-bp fragment of the gene
by use of the primers HT2A_ex.2(5)F (5′-GGTGTGAC-
TGACAGCTATG-3′) and HT2A_ex.2(6)R (5′-CATAG-
GCTGAGTCTATTCTGC-3′) from the genomic DNA of
an unaffected individual. The fragment was subjected to
electrophoresis in a 1% agarose gel, was purified as de-
scribed in the “DNA Analysis” subsection, and was then
labeled using the Random Primers Labeling kit (Invitro-
gen). A product with a specific activity of cpm/93# 10
mg was obtained. The blot was hybridized using Ultra-
hyb hybridization solution (Ambion) according to the
manufacturer’s instructions. The hybridized membrane
was visualized by autoradiography with Biomax MS film
(Kodak). Film exposure was performed at 80C, with
intensifying screens, for 100 h.
Reverse-transcriptase PCR (RT-PCR) was performed
on RNA that was isolated from cultured skin fibro-
blasts obtained from both an affected individual and
an unaffected individual. RNA was isolated using an
Oligotex Direct mRNA Isolation kit (Qiagen), and first-
strand synthesis was performed using the Expand RT
system (Roche) according to the manufacturers’ in-
structions. Primers used for amplification of the PAPPA
gene were PAPPA16/17 (5′-AACGGGCCTTCAAGAC-
TCAG-3′) and PAPPA19/20 (5′-ACAACTCTCTCTAC-
CCGTG-3′).
Results
Haplotype Analysis
Haplotype analysis was performed both to define the
order of markers used and to fine map the candidate
region. Genotypes were obtained for the population that
we studied and for selected CEPH individuals, and then
haplotypes were constructed (complete data not shown).
Three recombination events were identified in individuals
C-06, C-07, and E-11, thereby reducing the candidate
region from 6.5 Mb to an interval of 713 kb flanked by
D9S241 and D9S931 (fig. 1). The region was further
reduced to a 560-kb region flanked by D9S1126 and
D9S737, on the basis of two inferred ancestral recom-
bination events (in individuals B-14 and E-23; fig. 1).
Physical Mapping
Our early physical-mapping efforts used a combina-
tion of Human Genome Project sequences and radiation-
hybrid mapping. Subsequent efforts focused on contig-
uous sequence obtained from the Celera Publication Site
(GA_x54KRCDB2PK: 3500001–4500000) (see fig. 2).
Four genes are present in the region, which spans 560
kb of DNA:
1 . PAPPA ( G e n B a n k a c c e s s i o n n u m b e r
NM_002581.1) encodes pregnancy-associated plasma
protein A (PAPPA, also known as “insulin-like growth
factor [IGF]–binding protein 4 [IGFBP4] protease”).
A high concentration of this protein is found in the
serum of pregnant women (Silahtaroglu et al. 1993;
Conover et al. 1999; Lawrence et al. 1999). The
IGFBP4-protease substrate, IGFBP4, is known to be
a potent inhibitor of the IGF-signaling system, and
PAPPA appears to prevent this inhibition.
2. Astrotactin 2 (ASTN2 [GenBank accession number
AF116574.1]) encodes a protein highly paralogous to
ASTN1, which is a mediator of neuronal-glial contact
(Edmondson et al. 1988).
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Figure 1 Chromosomal region 9q31-33 haplotypes, showing recombinations (in individuals C-06, C-07, and E-11) that reduce the 6.5-
Mb LGMD2H candidate region, flanked by D9S302 and D9S1850, to a 713-kb region, flanked by D9S241 and D9S931. Inferred ancestral
recombinants in individuals B-14 and E-23 further reduce the region to an interval of 560 kb, flanked by D9S1126 and D9S737 (boxed regions
in the columns of markers). Individuals in family C (individuals C-01, C-02, and C-05–C-09) are represented as C-5, C-6, and C-18–C-22,
respectively, by Weiler et al. (1998). Individuals in families B and E were not included in the study by Weiler et al. (1998). Blackened diamonds
represent affected individuals, unblackened diamonds represent unaffected individuals, and unblackened diamonds with a question mark (?)
represent individuals with unknown phenotype. Alleles are given (in bp), and “0” indicates that no data are available. Blackened backgrounds
behind haplotypes indicate consensus disease-associated alleles, square brackets indicate inferred alleles, and the absence of an outer vertical
border indicates that an allele is uninformative for a crossover. See table 1 for the alleles of V1–V4. Alleles of D9S1850 were reevaluated for
this study, and some are 2 bp larger than those reported by Weiler et al. (1998).
3. TRIM32 (GenBank access ion number
NM_012210.2), previously known as “HT2A” (Fri-
dell et al. 1995), encodes a member of the TRIM fam-
ily of proteins. It was originally discovered using a
yeast two-hybrid assay with the human immunode-
ficiency virus type 1 Tat acting as bait (Fridell et al.
1995; Reymond et al. 2001). The RING-finger do-
main suggests that this protein is an E3-Ub ligase.
4. Sequencing of orphan expressed-sequence tag
(EST) clones revealed a putative fourth gene in the region
(data not shown). The 5′ end of this gene is still unde-
fined, but the 3′ end consists of at least four exons found
in the cDNA clone IMAGE:2591170 (GenBank acces-
sion number AW090658.2). Attempts to amplify and
sequence the 5′ end of this gene have been unsuccessful
owing to the apparent rarity of the transcript in all tis-
sues that we have studied, including muscle (data not
shown).
Mutation Screening
All four aforementioned genes were considered as po-
tential candidates for LGMD2H, on the basis of their
chromosomal position. Both SSCA and DNA sequencing
were used to search for disease-causing mutations. SSCA
of exons located between the flanking microsatellitemark-
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ers D9S1126 and D9S737 revealed only one silent sub-
stitution (i.e., V3) in PAPPA. DNA sequencing of the
exons of the candidate gene shown in fig. 2 revealed three
more sequence variations (V1, V2, and V4). We were
unable to detect V2 and V4 by SSCA in our initial screen;
however, subsequent amplification in a smaller-sized PCR
product allowed visualization of both alleles of V2 and
of V4, by SSCA. The four sequence variations—an 11-
bp deletion and three point mutations—were identified
on the basis of differences between sequences from an
affected individual and published sequences (table 1). V1,
an 11-bp deletion in intron 2 of PAPPA, can be excluded
as the disease-causing mutation, because it does not seg-
regate withLGMD2H and is outside the candidate region
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Figure 2 Physical map of the LGMD2H candidate region, flanked by D9S1126 and D9S737. The four sequence variations identified in
samples from patients are labeled “V1”–“V4”, as in table 1. The map shows 1 Mb and is based on contiguous sequences obtained from
GenBank and the Celera Publication Site.
as defined by an inferred ancestral recombination event
(in individual E-23; fig. 2). Both affected and unaffected
family members were homozygous for the deletion, and
it was common among controls (fig. 1 and table 1). V2,
a missense mutation in codon 1224 of PAPPA, can also
be excluded as a disease-causing mutation. All affecteds
and all but one of the obligate carriers (i.e., individual E-
02; fig. 1) are homozygous for the V2(Tyr) allele. Both
alleles of V1 and of V2 are common in Hutterite families
and controls.
V3 results in a silent substitution in codon 1458 of
PAPPA. The V3(T) allele was found to have a frequency
of 2% in controls. Since the V3 mutation does not
change the amino acid sequence of PAPPA, it could be
disease causing if it leads to alternate splicing or if the
codon usage of the V3(T) allele is significantly different.
However, codon usage does not appear to be a factor,
since the two coding triplets are used at similar fre-
quencies in humans; UGC accounts for 55% of all cys-
teine codons, and UGU accounts for 45% of all cysteine
codons (Codon Usage Database). Alternative splicing is
unlikely because in silico analysis of the splice consensus
sequences shows no predicted change with the intro-
duction of V3(T) (NIX package; U.K. Human Genome
Mapping Project Resource Centre). RT-PCR was used
to confirm this prediction by amplifying the region con-
taining V3 (PAPPA exons 17–19), from both affected
and unaffected RNA isolated from cultured skin fibro-
blasts. No differences between the affected and unaf-
fected samples were apparent (data not shown).
V4 results in a nonconservative substitution of an
acidic aspartate by a neutral asparagine at amino acid
487 of TRIM32. The V4(Asn) and V3(T) alleles are in
complete linkage disequilibrium in the Hutterite fami-
lies. The V4(Asn) allele was not observed in any of the
controls. All 35 affected individuals in whom LGMD2H
had been diagnosed are homozygous for V4(Asn) and
V3(T). There were six asymptomatic individuals who
were also homozygous for these alleles and the disease-
associated chromosome. Four of these individuals are
!20 years of age, which is consistent with our previous
findings that the onset of LGMD2H is age dependent
(Weiler et al. 1998). The other two individuals are in
their 30s and do not meet the strict criteria for affected
individuals that have been established by Weiler et al.
(1997).
The V4 amino acid substitution occurs within the
third NHL (named after the proteins NCL1, HT2A
[TRIM32], and LIN-41 [Slack and Ruvkun 1998]) do-
main of TRIM32. NHL domains are conserved motifs
found in many prokaryotic and eukaryotic proteins. This
missense mutation occurs at one of the two most highly
conserved positions in this domain (table 2) (Slack and
Ruvkun 1998).
Northern Blot Analysis
LGMD2H is a disease that is mainly restricted to skel-
etal muscle. Evidence from ESTs (UniGene accession
number Hs.236218) suggests that the TRIM32 tran-
script is expressed in a wide variety of tissues, including
skeletal muscle. To confirm the presence of the transcript
in skeletal muscle, we probed a multiple-tissue northern
blot (Origene Technologies) with a 733-bp fragment ob-
tained from the coding sequence of TRIM32. The results
(shown in fig. 3) indicate that the transcript is indeed
widely expressed and, in particular, is expressed in skel-
etal muscle.
Discussion
On the basis of observed recombinants, the candidate
gene for LGMD2H was previously defined to be in a
3.9–6.2-cM interval flanked by D9S302 and D9S1850
(Weiler et al. 1998). The region could be reduced to a
0.3-cM interval flanked by D9S302 and D9S934 by as-
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Table 2
Alignment of Selected NHL Domains from Nine Eukaryotic Species
SOURCE
AMINO ACID
Position Sequence
Consensus sequence 1–27 FDYPRGVAVDSDGO-IVVADSE––N
Species and proteina (GenBank accession number):
Homo sapiens:
TRIM32 (NP_036342.1) 371–398 FNLPVSLYVTSQGE-VLVADRG––N
428–455 NLTPLSVAMNCQGL-IGVTDSY––D
469–496 LSKPWGITALPSGQ-FVVTDVE––G
520–550 TCDAEGTVYFTQGLGLNL-ENRQNE
575–602 FRCIAGMCVDARGD-LIVADSS––R
616–643 LTCPVGIALTPKGQ-LLVLDCW––D
PAM (NP_000910.1) 683–711 FTVPHSLALVPLLGQLCVADRE––N
TRIM2 (NP_056086.1) 534–561 FTNLQGVAASTNGK-ILIADSN––N
TRIM3 (NP_006449.1) 533–560 LQRPTGVAVDTNGD-IIVADYD––N
Caenorhabditis elegans:
NCL1 (AAC14263.1) 586–613 FTEPSGVAVNGQGD-IVVADTN––N
633–662 LLYPNRVAVNRTTGDFVVTERS––P
677–704 LQHPRGVCVDSKGR-IIVVECK––V
720–747 LEFPNGVCTNDKNE-ILISDNR––A
LIN-41B (AAF15530.1) 763–791 TNYPIGVGINSLGE-VVVADNH-NN
845–872 LCRPWGICVDQRGR-VIVADRS––N
892–919 FDRPAGITTNSLNN-IVVADKD––N
939–966 FNYPWGVATNSHNA-IAVSDTR––N
987–1014 LDSPRGLCYLPDGQ-LLITDFN––N
1035–1062 FVRPQGVVIDPEGH-ILVCDSR––N
1120–1147 LDRPTDLAVGPDGR-IYVVDFG––N
YMB4 (CAA79562.1) 712–739 LNWPRGICALSGGL-VATCDSS––N
F26F4.6 (AAA91222.1) 761–788 LHCPSGFCLSDTDD-ILIADTN––N
F21F3.1 (AAB42278.1) 279–307 FVVPHSLSLIEDMNIVCVADRE––N
PAM (AAB37637.1) 424–451 FYLPHGIYVDKDGF-VYTTDVG––S
Mus musculus:
Pam (NP_038654.1) 581–608 FYLPHGLSIDTDGN-YWVTDVA––L
Trim3 (BAA83343.1) 713–740 LYGPQGLALTSDGH-VVVADAG––N
Rattus norvegicus:
Pam (NP_037132.1) 581–608 FYLPHGLSIDTDGN-YWVTDVA––L
Trim3 (AAC17997.1) 486–513 FTNLHPLSAASSGR-IVVADSN––N
Bos taurus PAM (AAA30683.1) 779–806 FDMPHDIAASEDGT-VYVGDAH––T
Equus caballus PAM (BAA06104.1) 682–710 FRVPHSLALVPHLGQLCVADRE––N
Xenopus laevis XELCAM (AAA49667.1) 582–610 FRIPHSLTMISDQGQLCVADRE––N
Drosophila melanogaster:
brat (AAF53771.1) 780–807 FTEPSGVAVNAQND-IIVADTN––N
dpld (AAF59245.1) 537–564 VSRPWGLCVDKMGH-VLVSDRR––N
cg12130 (AAF58870.1) 387–415 FQNPHDVAVTADGNEIYVAELN––P
Lymnaea stagnalis LPAM (AAD42258.1) 1578–1605 YFMPHGIEVDNQGN-LWLTDVA––L
a Each protein has up to six NHL domains (InterPro accession number IPR001258); however, only
one domain from each protein is shown, except for the three after which the NHL domain was named
(i.e., NCL1, HT2A [TRIM32], and LIN-41). There are six domains from TRIM32, and the mutation
(i.e., D487N) is in the third NHL domain, at position 20, denoted by the underlined letter in each
sequence. This aspartate is one of the most highly conserved amino acids among the NHL domains.
There are currently 110 eukaryotic NHL domains in the InterPro database; of these, at position 20, 100
have an aspartate, 9 have a glutamate, and 1 has a lysine.
suming that an ancestral recombination had occurred
(Weiler et al. 1998). This interval is now estimated to
be 4.1 Mb (UCSC Human Genome Project Working
Draft). Through the study of additional families with
LGMD2H and the use of 22 additional microsatellite
markers, we have reduced the candidate region to a 560-
kb interval flanked by D9S1126 and D9S737, on the
basis of haplotype analysis. The region contains three
annotated genes—PAPPA, ASTN2, and TRIM32—and
one unannotated gene. TRIM32 is located within intron
12 of ASTN2, in the opposite orientation, and part of
the unannotated gene is within introns 9 and 10 of
PAPPA, in the opposite orientation (fig. 2).
All exons within the candidate region were screened
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Figure 3 Northern blot analysis using a fragment of theTRIM32
coding sequence. TRIM32 shows two transcript sizes, 3.3 and 2.5 kb.
Expression is evident in skeletal muscle, but levels appear much higher
in brain and heart tissue.
for mutations. Of the four sequence variations detected,
V1 and V2 could readily be excluded as disease causing
because they do not consistently segregate with disease.
V3(T) appears to be an unlikely candidate because it
leads neither to an amino acid change, to a codon with
significantly altered usage, nor, apparently, to alterna-
tive splicing. The latter was confirmed by RT-PCR of
mRNA isolated from skin fibroblasts that were obtained
from one patient and from a control. However, at this
time, we cannot exclude the possibility that the V3(T)
allele either disrupts an exonic splicing enhancer that
functions only in muscle (Liu et al. 1998, 2001) or alters
the secondary structure of the mRNA (Shen et al. 1999).
The best candidate mutation for LGMD2H is the
missense mutation V4, in TRIM32, which changes co-
don 487 of TRIM32 from aspartate to asparagine
(D487N). There is strong evidence that this D487N mu-
tation causes LGMD2H, because (1) all affected indi-
viduals in our study are homozygous for V4(Asn); (2)
the D487N mutation was not observed in 100 controls;
(3) the D487N mutation occurs in a protein domain
that is considered to be an NHL domain (Slack and
Ruvkun 1998) and is found in many proteins, and the
aspartate in question is one of the two most conserved
amino acids in NHL domains (table 2); and (4) the
mutation from aspartate to asparagine is a nonconser-
vative change that could result in a significant alteration
in the structure and function of TRIM32. Thus, we
consider D487N to be the disease-causing mutation for
LGMD2H in the patients whom we studied. The in-
formation that we currently possess does not exclude
the possibility that V3 may contribute additional effects
to the phenotype.
TRIM32 has, from N- to C-terminal ends, a RING-
finger domain, a B1 box, a coiled-coil domain, and six
NHL domains (InterPro accession numbers IPR001841,
IPR002991, IPR003649, and IPR001258, respectively)
(Apweiler et al. 2001). TRIM32 is a member of a grow-
ing family of TRIM, or RING–B-box–coiled-coil, pro-
teins (Reymond et al. 2001; Torok and Etkin 2001).
Current knowledge of the RING-finger domain indi-
cates that it may have intrinsic Ub-ligase activity (Bar-
inaga 1999), and it has been suggested that all RING-
finger proteins are E3-Ub ligases (Freemont 2000). This
information suggests that TRIM32 is an E3-Ub ligase
that functions in the Ub-proteasome pathway.
The Ub-proteasome pathway is a specialized mech-
anism for the posttranslational regulation of protein
levels. The initial step in the Ub-proteasome pathway
is the activation of Ub by an E1-Ub–activating enzyme.
The activated Ub is transferred to the E2-Ub–conju-
gating enzyme. The E3 ligase interacts with E2-Ub com-
plex and recruits a protein to be targeted to the 26S
proteasome. The E3 ligase catalyzes the transfer of Ub
to the target protein. The ubiquitinated protein is re-
leased from the complex and is recognized by factors
associated with the 26S proteasome. The 26S protea-
some digests the ubiquitinated protein into small pep-
tides. The E3 enzymes are responsible for the selection
of proteins for ubiquitination by this pathway, and it
is thought that a large number of these enzymes exist
(Freemont 2000). It has been shown that the RING-
finger domain of an E3 ligase mediates interaction with
the E2-conjugating enzyme and is the source of the li-
gase activity (Joazeiro and Weissman 2000). This sug-
gests that recognition of target proteins by E3 ligases
occurs through protein-protein interactions with areas
of the protein other than the RING-finger domain. In
the case of TRIM32, this function may be fulfilled by
a series of NHL domains.
NHL domains have been shown to be important for
the function of a number of proteins—including LIN-
41, in Caenorhabditis elegans, and brat, in Drosophila
melanogaster, both of which act as posttranscriptional
repressors. Of the seven apparent loss-of-function lin-
41 mutations that are discussed by Slack et al. (2000),
five lead to amino acid substitutions found in the NHL
domains (Slack et al. 2000). Loss-of-function brat mu-
tations include both deletions of the NHL domains and
missense mutations (Arama et al. 2000; Sonoda and
Wharton 2001). All of these mutations abolish an in-
teraction with another protein, thereby leading to func-
tional consequences.
This information suggests interesting possibilities as to
the role of TRIM32 in LGMD. If TRIM32 is indeed an
E3-Ub ligase, then the NHL domains could mediate in-
teraction either with other members of an E3-Ub–ligase
complex or with the proteins that the complex targets to
the proteasome. Because of both the limited distribution
of symptoms in patients with LGMD2H and the wide
tissue distribution of TRIM32, it is tantalizing to pos-
tulate that the third NHL repeat is involved in the in-
teraction with—and, therefore, the targeting of—one or
a group of proteins to the proteasome to be degraded.
A mutation in the NHL domain would prevent this pro-
cess, and these target proteins would accumulate to
higher concentrations. The restriction of symptoms to
muscle tissue may have two explanations: (1) the third
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NHL domain may be interacting with muscle-specific
proteins; and (2) although the increased level of proteins
is not restricted to muscle, it may have a toxic effect only
in muscle. Increased levels of some proteins have been
reported to cause myopathic symptoms, as has been
shown in work involving transgenic mouse lines that
overexpress either caveolin-3 (Galbiati et al. 2000) or g-
sarcoglycan (Zhu et al. 2001). Furthermore, the gene
mutated in rare forms of Parkinson disease, PARK2, is
thought to work via a similar pathogenic mechanism.
Parkin, the product of PARK2, is known to be a RING-
finger–containing E3-Ub ligase (Shimura et al. 2000). The
neuronal death seen in Parkinson disease is thought to
be a direct result of the accumulation of proteins that
are no longer ubiquitinated by mutant forms of parkin
and that, therefore, are not degraded by the proteasome
(Imai et al. 2001; Shimura et al. 2001). Studies to de-
termine whether TRIM32 is indeed an E3-Ub ligase and
to identify a similar pathogenic mechanism in parkin are
currently under way.
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